The small-molecule inhibitors calyculin A and okadaic acid have been used to mitigate PP1 and PP2A activity, thereby impairing the progression of hormone therapy-resistant prostate cancer by stimulating cell death59. This evidence concerns the gene PTPA and Familial prostate cancer.